Shots:

• The companies reported that the first cohort of BioNTech’s P-I/II clinical trial has dosed 12 participants with BNT162 in Germany since dosing began on Apr 23- 2020. Following the regulatory approvals- both the companies plan to initiate the clinical study for BNT162 in the US
• The dose-escalation portion of the P-I/II study will include ~200 healthy participants aged 18-55yrs. and will target a dose range of 1-100 µg- focusing on determining the optimal dose for further studies and to evaluate the safety and immunogenicity of the vaccine
• The study will evaluate the effects of repeated vaccination following a prime injection for 3 vaccine candidates that contain uRNA or modRNA. The fourth vaccine candidate contains saRNA will be evaluated following a single dose of vaccine. Additionally- BioNTech is collaborating with Fosun Pharma to develop BNT162 in China- where the companies expect to conduct clinical studies

Click here ­to­ read full press release/ article | Ref: BioNTech | Image: OMR Industry Journal

Related News: Pfizer and BioNTech to Commence Clinical Study for COVID-19 in Germany